

# POST-TEST/CE EVALUATION FORM

## CLINICALLY MEANINGFUL RESPONSE IN MDD: A MULTIDISCIPLINARY APPROACH

Date: \_\_\_\_\_ Center: \_\_\_\_\_

City, State: \_\_\_\_\_ Activity ID: 10194 EJ 29/10195 UJ 29

---

- 1. Assessment of depression should include a mental status examination.**
  - a. True
  - b. False
  
- 2. Which of the following is not a risk factor for treatment-resistant depression?**
  - a. Alcohol or substance abuse
  - b. Late age of onset of depression
  - c. History of attempted suicide
  - d. Anxiety disorder
  
- 3. What comorbid conditions can contribute to treatment-resistant depression?**
  - a. Cerebrovascular disease
  - b. Substance abuse
  - c. Neurodegenerative disorders
  - d. All of the above
  
- 4. Which of the following medications can cause symptoms of depression?**
  - a. Acetaminophen
  - b. Bupropion
  - c. Clonidine
  - d. None of the above
  
- 5. Short depression screening scales include all except:**
  - a. MADRS
  - b. CUDOS
  - c. QIDS
  - d. PHQ-9
  
- 6. Which of the following newer antidepressants is approved for bipolar depression only?**
  - a. Vilazodone
  - b. Lurasidone
  - c. Levomilnacipran
  - d. Vortioxetine
  
- 7. What constitutes an adequate trial of an antidepressant?**
  - a. Should continue for more than 4 weeks at a full therapeutic dose
  - b. Whenever possible the dose should be increased above the minimum
  - c. Intolerance and residual symptoms do not equal nonresponse
  - d. All of the above
  
- 8. In the STAR\*D trial, two-thirds of responders responded by:**
  - a. Week 2
  - b. Week 4
  - c. Week 6
  - d. Week 8



**17. Please select the extent to which you agree/disagree that the activity supported the achievement of each learning objective:**

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Utilize comprehensive history-taking and assessment tools to monitor for, and identify, inadequate treatment response and residual symptoms in major depressive disorder (MDD)	⑤	④	③	②	①
Implement appropriate treatments for MDD that address all symptoms of the disorder, including new and emerging antidepressants	⑤	④	③	②	①
Integrate into practice strategies for managing patients with partial response, or non-response in MDD	⑤	④	③	②	①
Provide appropriate care and counsel for patients and their families	⑤	④	③	②	①

**18. Rate how well the activity achieved the following:**

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
The faculty were effective in presenting the material	⑤	④	③	②	①
The content was evidence-based	⑤	④	③	②	①
The educational material provided useful information for my practice	⑤	④	③	②	①
The activity enhanced my current knowledge base	⑤	④	③	②	①
The activity provided appropriate and effective opportunities for active learning (eg, case studies, discussion, Q&A, etc)	⑤	④	③	②	①
The opportunities provided to assess my own learning were appropriate (eg, questions before, during or after the activity)	⑤	④	③	②	①

**19. Based upon your participation in this activity, do you intend to change your practice behavior? (choose only one of the following options)**

- I do plan to implement changes in my practice based on the information presented
- My current practice has been reinforced by the information presented
- I need more information before I will change my practice

**20. Thinking about how your participation in this activity will influence your patient care, how many of your patients are likely to benefit?**

Please use a number (example 250): \_\_\_\_\_

**21. If you plan to change your practice behavior, what type of changes do you plan to implement? (check all that apply)**

- Apply latest guidelines
- Change in pharmaceutical therapy
- Change in non-pharmaceutical therapy
- Change in diagnostic testing
- Choice of treatment/management approach
- Change in current practice for referral
- Change in differential diagnosis
- Other, please specify: \_\_\_\_\_

